The fourth batch of national Chinese patent medicine alliance procurement bid opening covers 89 commonly used clinical medicines

On April 30th, the fourth batch of the National Chinese Patent Medicine Alliance Procurement (referred to as “National Joint Procurement”) opened bids in Wuhan and announced the proposed winning results.
This centralized procurement included 28 procurement groups and 89 types of medicines, with over 40k medical institutions across the country participating in submitting bids.
A total of 344 companies with 468 products met the bidding requirements, and 243 companies with 310 products were selected.
Overall, companies actively participated in bidding, with a complete range of approved dosage forms and specifications, and the mainstream products currently used in clinical practice were generally selected, effectively meeting clinical medication needs. (People’s Financial News)

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin